Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression

Lynnette Shorts, Jonathan M. Weiss, Jong Keuk Lee, Lisbeth A. Welniak, Jeffrey Subleski, Timothy Back, William J Murphy, Robert H. Wiltrout

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

CD40, a member of the TNFR superfamily, is expressed on a variety of host immune cells, as well as some tumors. In this study, we show that stimulation of CD40 expressed on both mouse and human renal carcinoma cells (RCCs) triggers biological effects in vitro and in vivo. Treatment of the CD40+ Renca mouse RCC tumor cells in vitro with an agonistic anti-CD40 Ab induced strong expression of the genes and proteins for GM-CSF and MCP-1, and induced potent chemotactic activity. Similarly, administration of αCD40 to both wild-type and CD40-/- mice bearing Renca tumors resulted in substantial amounts of TNF-α and MCP-1 in the serum, increased the number of total splenocytes and MHC class II+ CD11c+ leukocytes, and when combined with IFN-γ, inhibited the progression of established Renca tumors in vivo in both wild-type and CD40-/- mice. Similarly, treatment of CD40+ A704 and ACHN human RCC lines with mouse anti-human CD40 Ab induced strong expression of genes and proteins for MCP-1, IL-8, and GM-CSF in vitro and in vivo. Finally, in SCID mice, the numbers of ACHN pulmonary metastases were dramatically reduced by treatment with species-specific human CD40 Ab. These results show that CD40 stimulation of CD40+ tumor cells can enhance immune responses and result in antitumor activity.

Original languageEnglish (US)
Pages (from-to)6543-6552
Number of pages10
JournalJournal of Immunology
Volume176
Issue number11
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Leukocytes
Cytokines
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Macrophage Colony-Stimulating Factor
SCID Mice
Interleukin-8
Proteins
Neoplasm Metastasis
Carcinoma
Kidney
Cell Line
Lung
Serum
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology

Cite this

Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. / Shorts, Lynnette; Weiss, Jonathan M.; Lee, Jong Keuk; Welniak, Lisbeth A.; Subleski, Jeffrey; Back, Timothy; Murphy, William J; Wiltrout, Robert H.

In: Journal of Immunology, Vol. 176, No. 11, 01.06.2006, p. 6543-6552.

Research output: Contribution to journalArticle

Shorts, Lynnette ; Weiss, Jonathan M. ; Lee, Jong Keuk ; Welniak, Lisbeth A. ; Subleski, Jeffrey ; Back, Timothy ; Murphy, William J ; Wiltrout, Robert H. / Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. In: Journal of Immunology. 2006 ; Vol. 176, No. 11. pp. 6543-6552.
@article{d4f2db7df89f40fc91a7fe880a04ed23,
title = "Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression",
abstract = "CD40, a member of the TNFR superfamily, is expressed on a variety of host immune cells, as well as some tumors. In this study, we show that stimulation of CD40 expressed on both mouse and human renal carcinoma cells (RCCs) triggers biological effects in vitro and in vivo. Treatment of the CD40+ Renca mouse RCC tumor cells in vitro with an agonistic anti-CD40 Ab induced strong expression of the genes and proteins for GM-CSF and MCP-1, and induced potent chemotactic activity. Similarly, administration of αCD40 to both wild-type and CD40-/- mice bearing Renca tumors resulted in substantial amounts of TNF-α and MCP-1 in the serum, increased the number of total splenocytes and MHC class II+ CD11c+ leukocytes, and when combined with IFN-γ, inhibited the progression of established Renca tumors in vivo in both wild-type and CD40-/- mice. Similarly, treatment of CD40+ A704 and ACHN human RCC lines with mouse anti-human CD40 Ab induced strong expression of genes and proteins for MCP-1, IL-8, and GM-CSF in vitro and in vivo. Finally, in SCID mice, the numbers of ACHN pulmonary metastases were dramatically reduced by treatment with species-specific human CD40 Ab. These results show that CD40 stimulation of CD40+ tumor cells can enhance immune responses and result in antitumor activity.",
author = "Lynnette Shorts and Weiss, {Jonathan M.} and Lee, {Jong Keuk} and Welniak, {Lisbeth A.} and Jeffrey Subleski and Timothy Back and Murphy, {William J} and Wiltrout, {Robert H.}",
year = "2006",
month = "6",
day = "1",
language = "English (US)",
volume = "176",
pages = "6543--6552",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression

AU - Shorts, Lynnette

AU - Weiss, Jonathan M.

AU - Lee, Jong Keuk

AU - Welniak, Lisbeth A.

AU - Subleski, Jeffrey

AU - Back, Timothy

AU - Murphy, William J

AU - Wiltrout, Robert H.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - CD40, a member of the TNFR superfamily, is expressed on a variety of host immune cells, as well as some tumors. In this study, we show that stimulation of CD40 expressed on both mouse and human renal carcinoma cells (RCCs) triggers biological effects in vitro and in vivo. Treatment of the CD40+ Renca mouse RCC tumor cells in vitro with an agonistic anti-CD40 Ab induced strong expression of the genes and proteins for GM-CSF and MCP-1, and induced potent chemotactic activity. Similarly, administration of αCD40 to both wild-type and CD40-/- mice bearing Renca tumors resulted in substantial amounts of TNF-α and MCP-1 in the serum, increased the number of total splenocytes and MHC class II+ CD11c+ leukocytes, and when combined with IFN-γ, inhibited the progression of established Renca tumors in vivo in both wild-type and CD40-/- mice. Similarly, treatment of CD40+ A704 and ACHN human RCC lines with mouse anti-human CD40 Ab induced strong expression of genes and proteins for MCP-1, IL-8, and GM-CSF in vitro and in vivo. Finally, in SCID mice, the numbers of ACHN pulmonary metastases were dramatically reduced by treatment with species-specific human CD40 Ab. These results show that CD40 stimulation of CD40+ tumor cells can enhance immune responses and result in antitumor activity.

AB - CD40, a member of the TNFR superfamily, is expressed on a variety of host immune cells, as well as some tumors. In this study, we show that stimulation of CD40 expressed on both mouse and human renal carcinoma cells (RCCs) triggers biological effects in vitro and in vivo. Treatment of the CD40+ Renca mouse RCC tumor cells in vitro with an agonistic anti-CD40 Ab induced strong expression of the genes and proteins for GM-CSF and MCP-1, and induced potent chemotactic activity. Similarly, administration of αCD40 to both wild-type and CD40-/- mice bearing Renca tumors resulted in substantial amounts of TNF-α and MCP-1 in the serum, increased the number of total splenocytes and MHC class II+ CD11c+ leukocytes, and when combined with IFN-γ, inhibited the progression of established Renca tumors in vivo in both wild-type and CD40-/- mice. Similarly, treatment of CD40+ A704 and ACHN human RCC lines with mouse anti-human CD40 Ab induced strong expression of genes and proteins for MCP-1, IL-8, and GM-CSF in vitro and in vivo. Finally, in SCID mice, the numbers of ACHN pulmonary metastases were dramatically reduced by treatment with species-specific human CD40 Ab. These results show that CD40 stimulation of CD40+ tumor cells can enhance immune responses and result in antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=33646862241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646862241&partnerID=8YFLogxK

M3 - Article

C2 - 16709811

AN - SCOPUS:33646862241

VL - 176

SP - 6543

EP - 6552

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -